Paper32099495
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.
Inoue H and 1 other. Lung Cancer (Auckl), 2019. Cited by 10 papers, by iCite.
Cite this record
ConductScience Library. Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives. Papers, record 32099495. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32099495
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20530281 | Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20530281 | PubMed |
| 2 | 27932443 | PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. | EMBO Mol Med | 2017 | https://conductscience.org/library/papers/27932443 | PubMed |
| 3 | 26712084 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. | Lancet | 2016 | https://conductscience.org/library/papers/26712084 | PubMed |
| 4 | 8011301 | Tolerance, danger, and the extended family. | Annu Rev Immunol | 1994 | https://conductscience.org/library/papers/8011301 | PubMed |
| 5 | 27565935 | Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. | Lung Cancer | 2016 | https://conductscience.org/library/papers/27565935 | PubMed |
| 6 | 27979383 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Lancet | 2017 | https://conductscience.org/library/papers/27979383 | PubMed |
| 7 | 24382348 | Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. | J Clin Invest | 2014 | https://conductscience.org/library/papers/24382348 | PubMed |
| 8 | 30280658 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30280658 | PubMed |
| 9 | 27468145 | PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. | Eur J Cancer | 2016 | https://conductscience.org/library/papers/27468145 | PubMed |
| 10 | 25274032 | Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. | Cancer Res | 2014 | https://conductscience.org/library/papers/25274032 | PubMed |
| 11 | 24331154 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/24331154 | PubMed |
| 12 | 25601342 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25601342 | PubMed |
| 13 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 14 | 25754814 | Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity. | Cancer Lett | 2015 | https://conductscience.org/library/papers/25754814 | PubMed |
| 15 | 30320184 | Immunogenic effects of chemotherapy-induced tumor cell death. | Genes Dis | 2018 | https://conductscience.org/library/papers/30320184 | PubMed |
| 16 | 12493003 | Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. | Immunol Rev | 2002 | https://conductscience.org/library/papers/12493003 | PubMed |
| 17 | 25534129 | A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. | Lung Cancer | 2015 | https://conductscience.org/library/papers/25534129 | PubMed |
| 18 | 23832118 | Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. | Cell Death Differ | 2014 | https://conductscience.org/library/papers/23832118 | PubMed |
| 19 | 26811519 | PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/26811519 | PubMed |
| 20 | 25481261 | Radiotherapy and immunogenic cell death. | Semin Radiat Oncol | 2015 | https://conductscience.org/library/papers/25481261 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40400937 | Expert consensus on cancer treatment-related lung injury. | J Thorac Dis | 2025 | https://conductscience.org/library/papers/40400937 | PubMed |
| 38203731 | Non-Coding RNAs as Key Regulators in Lung Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203731 | PubMed |
| 37781162 | Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis. | EClinicalMedicine | 2023 | https://conductscience.org/library/papers/37781162 | PubMed |
| 35967142 | The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression. | Cureus | 2022 | https://conductscience.org/library/papers/35967142 | PubMed |
| 35330063 | Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment. | J Clin Med | 2022 | https://conductscience.org/library/papers/35330063 | PubMed |
| 33860055 | Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/33860055 | PubMed |
| 33628725 | Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients. | Front Oncol | 2020 | https://conductscience.org/library/papers/33628725 | PubMed |
| 32833338 | Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review. | Thorac Cancer | 2020 | https://conductscience.org/library/papers/32833338 | PubMed |
| 32513983 | Circular RNA circSLC25A16 contributes to the glycolysis of non-small-cell lung cancer through epigenetic modification. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/32513983 | PubMed |
Genes27
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32099495
GET https://conductscience.org/api/papers/v1/32099495/references?page=2